Definition of Terms and Concepts 2.1 Temporary and Permanent Implants
Interstitial implants fall into two general categories, temporary or permanent. In temporary implants, the radioactive sources are removed from the tissue after the treatment is completed. In contrast, in permanent implants, the sources remain in the tissues.
In temporary implants, the radioactive sources are generally linear (wires) or arranged in a linear fashion (seed ribbons, etc.), whereas in permanent implants, multiple point sources are not distributed, in general, in linear arrays. The latter type of source pattern is considered separately in this Report.
In planning temporary implants, the total time of implantation depends on the number of sources, their strength and pattern. In contrast, in permanent implants, the number of sources depends on their initial strength.
In temporary implants, in the event of a non-ideal source pattern, there may be the possibility ofimproving the associated dose distribution through manipulation of the dwell time of some sources in the implant. However, no such possibility exists in the case of permanent implants.
Source Specification
(see also AppendixA.2.)
The Reference Air Kerma Rate of a brachytherapy source is the kerma rate to air, in air, at a reference distance of1 meter, corrected for air attenuation and scattering. For this purpose, this quantity is expressed in mGy.h-1 at one meter, or ,uGy.h-1 at one meter.
Description of Source Patterns (see also
Section 3.1.2)
Since essentially all implants irradiate a volume of tissue, the term "volume implant" should not be used to describe a specific implant. A more accurate description of the source pattern is required. Commonly employed source patterns are briefly described as follows: (i) A single plane implant is defined as an implant containing two or more sources which lie in the same plane. In some instances, the sources lie in a single curved surface. (ii) A two plane implant contains two planes which are generally parallel to each other. (iii) Larger implants can often be described according to the number of planes of sources used. (iv) If the implant is not formed in recognizable planes, then it may be described by the loca-tion of the sources relative to a plane passing through the center of the implant or by a specific geometrical configuration (e.g., sphere or cylinder).
Total Reference Air Kerma
The total reference air kerma (TRAK) is the sum of the products of the reference air kerma rate (see Appendix A.2) and the irradiation time for each source. It is analoguous to mg.h, proportional to the integral dose to the patient, and can also serve as a useful index for radiation protection of personnel.
The simple determination of the total reference air kerma does not, however, allow one to derive, even approximately, the absorbed dose in the immediate vicinity of the sources (i.e., in the tumor or target volume).
Volumes and Planes
The definitions of gross tumor volume and clinical target volume are entirely based on general oncological principles and, thus, are identical to the definitions given for external beam radiotherapy (see ICRU Report 50, ICRU, 1993).
Gross Tumor Volume
The gross tumor volume (GTV) is the gross palpable or visible/demonstrable extent and location ofthe malignant growth.
According to the above definition, there is no gross tumor volume after complete "gross" surgical resection. There is no gross tumor volume when there are only a few individual cells or "subclinical" involvement (even histologically proven).
Clinical Target Volume
The clinical target volume (CTV) is a tissue volume that contains a gross tumor volume and/or subclinical microscopic malignant disease which has to be eliminated. This volume thus has to be treated adequately in order to achieve the aim of therapy: cure or palliation.
The clinical target volume must always be described, independently of the dose distribution, in terms of the patient's anatomy and the tumor volume. The clinical target volume is a tissue volume intended to be irradiated according to a specified dose-time pattern. As a minimum, the physical dimensions ofthe clinical target volume are described in terms of its maximum dimension (cm) in three orthogonal directions (see Figure 2 .1). In external therapy, the two steps, clinical target volume localization and treatment planning can always be dissociated and therefore checked separately. However, the clinical target volume in interstitial therapy is sometimes decided upon by the clinician at the time of implantation, on the assumption that it is contained within the minimum target isodose (see Section 2.6.4). This procedure is not recommended. The clinical target volume should be clearly described in the patient chart before the implant is planned.
Planning Target Volume
In external therapy, to ensure that all the tissues included in the clinical target volume receive the appropriate dose, it is sometimes necessary to plan the irradiation of a larger volume: the planning target volume. In interstitial brachytherapy, the planning target volume is, in general, identical to the clinical target volume with very few exceptions. For instance, with some techniques in which there are uncertainties of consistency of source positions (high dose rate, moving sources, fractionated techniques) or alteration of source position (permanent implants) during the application, the planning target volume may be larger than the clinical target volume to take these factors into account.
In this Report, the term clinical target volume is used rather than planning target volume.
Treated Volume
The treated volume is that volume of tissue, based upon the implant as actually achieved, which is encompassed by an isodose surface selected or specified by the radiation oncologist as being appropriate to achieve the purpose of treatment (e.g., tumor eradication, palliation). The dose value at this isodose surface is the minimum target dose (see Section 2.6.4). This isodose surface should, ideally, entirely encompass the clinical target volume.
Central Plane
In source patterns in which the source lines are straight, parallel, of equal length and with centers which lie in a plane perpendicular to the direction of the source lines, this plane is the central plane (see Section 2.6.5 and Figure 2 .4).
In an actual implant, all source lines may not necessarily be straight, parallel and of equal length. In such cases, the central plane should be chosen perpendicular to the main direction of the source lines and passing through the estimated center of the implant.
For more complex implants, it may be necessary to subdivide the target volume into two or more subvolumes for dose evaluation. In this event, a central plane may be defined for each of these subvolumes (see Section 2.6.5).
The calculation of dose distributions in multiple planes throughout the target volume shows that a variation of a few millimeters, in the position of the central plane, is not critical.
Description of Dose Distribution

General Concepts
In brachytherapy, the dose distribution is nonhomogenous and includes steep dose gradients and regions of high dose surrounding each source. However, within the volume of the implant, there are regions where the dose gradient approximates a plateau (see Figure 2 .2).
(i) In an interstitial implant, the regions of plateau dose are equidistant between adjacent neighbouring sources, for sources of identical linear activity. They are regions oflocal minimum doses. (ii) Variations in the dose between the different plateau doses can be used to describe the dose uniformity of an implant. (iii) A region of plateau dose is the place where the dose can be calculated most reproducibly and compared easily by different departments. Plateau dose region between radioactive sources. The dose distribution in a plane perpendicular to linear and parallel sources, shows a plateau dose region of low dose gradient. In this example of three sources 6 cm long and with 1.5 em spacing, the dose varies by less than 2% in the gray region between the sources. (After Dutreix et aI., 1982).
Dose Distributions in One or More Planes through the Implant
Although, in modern computer systems, the 3-D dose distribution can be computed and presented as isodose surfaces, these facilities are not yet available in many departments.
In order to provide the minimum of information needed about the dose or dose-rate distribution, the calculation of isodose curves in at least one chosen plane is necessary.
Methods to present dose information, either in tabular form or by graphical presentation have been discussed in ICRU Report 42 (ICRU, 1987) .
If only one plane is chosen for isodose calculation, the central plane of the implant (as defined in Section 2.5) should be chosen for this purpose. In order to assess the dose distribution in other areas of the implant, multiple planes for isodose calculation can be chosen, either parallel or perpendicular to the central plane.
Prescribed Dose
For purposes of this Report, the prescribed dose is defined as the dose which the physician intends to give and enters in the patient's treatment chart. Depending on the system used, the approach for dose prescription may be different. It is not the intention of this Report to encourage users to depart from their normal practice of dose prescription.
Minimum Target Dose
The minimum target dose (MTD) is the minimum dose at the periphery of the clinical target volume. It should be equal to the minimum dose decided upon by the clinician as adequate to treat the clinical target volume.
The minimum target isodose is the isodose surface corresponding to the minimum target dose. It defines the treatment volume and should entirely encompass the clinical target volume (see Section 2.4). The MTD is known in some American centers as the minimu peripheral dose. The word peripheral is not recommended as being too vague and leading to confusion with the concept of peripheral dose in external therapy referring to the dose to healthy structures outside of the target volume. The MTD is known as the reference dose in the Paris System. The MTD is equal to about 90% of the prescibed dose in the Manchester system for interstitial therapy.
Mean Central Dose
In the field of brachytherapy, the mean central dose (MCD) is taken to be the arithmetic mean ofthe local minimum doses between sources, in the central plane, or in the central planes if there are more than one.
In the case of a single plane implant, the mean central dose is, in the central plane, the arithmetic mean of the doses at mid distance between each pair of adjacent source lines, taking into account the dose contribution at that point from all sources in the pattern (see Figures 2.3a and 2.3c).
In the case of implants with line sources in more than one plane, the mean central dose is the arithmetic mean of the local minimum doses between each set of three adjacent source lines within the source pattern (Figures 2.3.b and 2.4). The minimum dose lies at the intersection of perpendicular bisectors of the sides of the triangles [geometric center] formed by these source lines. This point is equidistant from all three source lines (see Figure 2 .2).
In some complex implants, a single central plane may not bisect or even include all the sources. In these cases, a mean central dose based on one plane can be misleading and it is advisable to subdivide the volume and to choose a separate central plane for each subvolume ( see Figure 2 .4) Three practical methods are acceptable for determining mean central dose. These include the following:
(i) In the case of implants with parallel lines, identify triangles consisting of three adjacent .-...
source lines for all the sources, so that the triangles formed constitute as many acute triangles as possible. Determine the intersection points of the perpendicular bisectors of each triangle and calculate the local minimum dose at each of these points. The mean of these local minimum doses is the mean central dose (see Figures 2.3 and 2.4) . This method is the most precise one for parallel lines. (ii) Evaluation of dose profiles: Calculate dose profiles for one or more axes through the center of the implant expected to pass through as many local minima as possible. Determine, by inspection, the local minimum doses. The mean of these local minimum values is the mean central dose (see Figure 2 .5). In a single surface implant performed following a curved surface, a profile may lead to an underestimation of the mean central dose. In a complex implant, it may be difficult to find axes passing through the minima and profiles may lead to an overestimation of the mean central dose.
However, examples show that the error lies within acceptable limits. This method is sometimes preferred for seed implants. In a seed implant, such as the one presented in Figure  2 .6, the dose should be calculated along several random profiles passing through the implant. (iii) Inspection of dose distribution: Plot the dose distribution in the central plane. With isodose lines varying by 5% (at most 10%) of the local dose in the central region, the local minima can be determined by inspection. The mean of these local minima is the mean central dose (see Figure 2 .7). This method is often preferred for complex implants with line sources.
High Dose Volumes
In order to correlate radiation dose with late damage, the high dose volumes around sources should be assessed. There will inevitably be a high dose zone around each source. Although it is often small and welltolerated, the exact tolerance dose and volume for interstitial therapy are not known. However, it is necessary, for intercom paris on purposes, to agree on a way to describe the high dose volumes. It is suggested that a dose of approximately 100 Gy is likely to be significant in determining late effects. In those patients who receive 50 to 60 Gy as minimum target dose or 60 to 70 Gy as mean central dose, 100 Gy correspond approximately to 150% of the mean cenral dose. It is therefore recommended that the size of the region receiving more than 150% of the mean central dose be reported.
The high dose volumes should be defined as the volumes encompassed by the isodose corresponding to 150% ofthe mean central dose around the sources in any plane parallel to the central plane where a high dose region is suspected. The maximum dimension of the largest region in all planes calculated should be reported (see Figure 2 .8).
Low Dose Volumes
A low dose volume should be defined as a volume within the clinical target volume, encompassed by an isodose corresponding to 90% of the prescribed In implants where the clinical target volume is included within the minimum target isodose, the occurence of a low dose region is exceptional. If the clinical target volume is not covered by the minimum target isodose, there will be low dose regions due to geographical miss.
In order to correlate the local recurrence rate with the dose distribution, it is recommended that low dose volumes be reported.
Dose Uniformity Parameters
Several indices quantifying the homogeneity ofthe dose distribution have been proposed (see, for ex- Fig. 2.7 . Inspection of dose distribution. Dose distribution in the central plane of an implant with 6 parallel Iridium line sources, 6 cm long, 1.5 cm spacing, reference air kerma-rate 14.5 jlGy.h-1 at one meter. The dose varies by 5% between plotted isodose lines in the region of interest (A, B, C, D) . The isodose values are 16, 19,22,24,26,28,30,31.5,33,35,40 and 45 cGy.h-1 . The local minima, A, B, C and D, can be easily estimated by inspection. DA and DD approximate 31 cGy.h-1 , and DB and Dc approximate 34 cGy.h-1 . The estimated mean central dose is Dm = 32.5 cGy.h-1 .
ample, Paul et al., 1988 , Wu et al., 1988 , Saw and Suntharalingam, 1991 .
In this Report, two parameters describing dose uniformity for interstitial implants are recommended. They can be derived directly from the concepts of minimum target dose and mean central dose (see Figure 2 .9):
(i) The spread in the individual minimum doses used to calculate the mean central dose in the central plane expressed as a percentage of the mean central dose. (ii) The dose homogeneity index;, defined as the ratio of minimum target dose to the mean central dose.
Additional Representations of the Dose Distribution
In order to obtain a full perception of the dose distribution of an implant, the use of volume-dose calculations has been advocated (see, for example, Neblett et al., 1985 , Anderson, 1986 , Bridier et al., 1988 , McCrae et al., 1987 . For this purpose, the clinical target volume (or a larger volume including an additional margin) is subdivided in subvolumes (e.g., voxels) and the dose rate is calculated at the center of each subvolume. The volume receiving at least a specified dose is then defined as the sum of all subvolumes where, at the center at least, that dose is received. Examples of results are shown in Figure  2 .10. Because of high dose gradients, significant differences in calculated volumes can be observed, depending upon the size of the elementary subvolumes. The size of the grid and of the elementary subvolumes (voxels) used in dose and volume calculations should be clearly stated. Volume-dose data can also be represented by means of histograms, showing the distribution of fractions of the clinical target volume receiving doses within chosen intervals. The value ofthese alternative representations of the dose distribution as possible prognostic factors for treatment outcome has still to be established in clinical research.
Time Dose Factors
General Considerations
Considerable experience has been gained over many years with conventional dose rates. For removable implants, 60-70 Gy has usually been delivered in 4 to 8 days at a dose rate of 30 to 90 centigrays per hour. For permanent implants with iodine-125, doses of 120 to 160 Gy have been delivered with 50% of the dose received in the first two months and the majority of the remainder over the succeeding six months. Even with these conventional treatments, it has been recognized that the dose rates within and adjacent to the target volume vary considerably as a function of the distance from the sources and that these variations may be significant in determining effects on both tumor and normal tissues.
The development of new afterloading techniques and, in particular, the use of high dose rate introduces new dose time patterns which require evaluation. These include:
Continuous low dose rate; with short scheduled or unscheduled interruptions. Single moving source high dose rate used to treat several channels of an implant over several days to simulate continuous low dose rate (see section 2.7.3: pulsed irradiation). High dose rate; in a single fraction. Fractionated high dose rate. Combinations of external beam radiation with any type of brachytherapy with varying intervals between the two. The overall treatment time for brachytherapy, and the duration of the interval(s) between treatments can have an important effect on outcome. Therefore, the dose time pattern should be recorded, and it is sometimes necessary to group different patterns for the purpose of analysis of outcome and intercomparisons. Relative dose (%) Fig. 2.10 . Volume-dose curves. Volume (sum of subvolumes receiving at least a certain dose) versus dose, for two different patterns of parallel source lines: a two plane implant with 6 sources 5 cm long (upper curve), and a cylindrical implant with 7 sources 4 cm long (lower curve). The dose is expressed in percentage ofthe minimum target dose. The size of the voxel used for calculations is 1 mm 3 • (Bridier et ai., 1988).
Times and Dose Rates for Temporary
Implants (see Figure 2 .11) Irradiation time is the time during which a radioactive source is present in the patient.
Overall treatment time is the total time elapsed from the beginning of the first irradiation to the end of the last one.
Instantaneous dose rate is the quotient of the dose and the irradiation time, for a given fraction or pulse.
Average overall treatment dose rate is the quotient of the total dose and the overall treatment time. Average overall treatment dose rate is a concept useful for continuous low dose-rate irradiations with or without short interruptions and for some pulsed irradiations (see Section 2.7.3).
Time Dose Pattern for Temporary
Implants (see the instantaneous dose-rate varies with time and the average overall treatment dose rate is, in general, meaningless.
Non-continuous irradiation. With the advent of remote afterloading, in most instances the overall treatment time is greater than the total irradiation time (which is the sum of the partial irradiation times) due to incidental or planned short interruptions during the treatment. The instantaneous dose rate is greater than the average overall treatment dose rate. In low dose-rate irradiations, when the duration of one given interruption is longer than 10% of the total irradiation time, the irradiation should be considered as fractionated.
Fractionated irradiation. In this type of treatment, irradiation time is subdivided into multiple fractions. In fractionated irradiation, the overall treatment time is much greater than the total irradiation time. For fractionated irradiation, the instantaneous dose rate is the ratio of the dose per fraction 10 and the irradiation time per fraction, and the average overall treatment dose-rate is, in general, meaningless.
Although the time interval between fractions is usually of the order of magnitude of a day or days, a low dose-rate irradiation is considered as fractionated when one given interruption is longer than 10% of the total irradiation time.
The special case of multiple short irradiations with high dose-rate source(s) is considered in the following paragraph.
Hyperfractionated irradiation. When two or more fractions are given per day, the irradiation is considered as an hyperfractionated irradiation. When the time interval between short high dose-rate irradiations reaches or exceeds four hours, the irradiation should be considered as a hyperfractionated irradiation. It should be considered as fractionated when the time interval is equal to one or several days.
Pulsed irradiation. When a single high doserate source is used to give a sequence of short irradiations (pulses) to simulate continuous low doserate irradiation, the irradiation should be considered as a pulsed irradiation as long as the time interval is shorter than four hours.
